Is Capivasertib (Truqap) in shortage in 2026? Get the latest update on availability, cost, and what you can do if you're having trouble finding it.
If you take Capivasertib (brand name Truqap) for breast cancer, you may have heard about drug shortages affecting oncology medications. Naturally, you might be wondering: Is Capivasertib in shortage right now? Can I still get my prescription filled?
This article provides a current update on Capivasertib availability in 2026, explains why patients are experiencing difficulty finding it, and outlines practical steps you can take to stay on your treatment.
As of early 2026, Capivasertib (Truqap) is not listed on the FDA Drug Shortage Database. This means there is no official, widespread manufacturing shortage of the drug.
However, many patients report difficulty getting their prescriptions filled. This is a common situation with newer, high-cost specialty oncology drugs — the medication is technically available, but access barriers make it feel like a shortage. The challenges are real, even if the cause is different from a traditional manufacturing shortage.
For background on why this happens, read our explainer: Why is Capivasertib so hard to find?
Several factors create access hurdles for patients:
Capivasertib is only available through specialty pharmacies — not your local retail pharmacy. This limits where you can fill your prescription and adds processing time.
Nearly all insurance plans require prior authorization before covering Truqap. Your oncologist must submit documentation confirming your diagnosis, tumor mutations (PIK3CA, AKT1, or PTEN), and prior treatment history. This process can take days to weeks.
You must have an FDA-approved companion diagnostic test (such as FoundationOne CDx) showing that your tumor has the required gene alterations. Waiting for test results adds time before treatment can even begin.
Some patients face initial insurance denials, particularly if documentation is incomplete or the plan has strict step therapy requirements. Appeals are possible but add further delay.
The cash price of Capivasertib is approximately $23,762 per 28-day cycle (64 tablets). This makes it one of the more expensive oral oncology medications on the market.
For commercially insured patients, out-of-pocket costs vary widely depending on your plan. Many patients are eligible for the Truqap Co-Pay Savings Program, which can reduce monthly costs to as little as $0.
If you're uninsured or underinsured, the AZ&Me Prescription Savings Program may provide Truqap at no cost. For a complete breakdown of savings options, see our article on how to save money on Capivasertib in 2026.
The treatment landscape for HR-positive, HER2-negative metastatic breast cancer continues to evolve. In addition to Capivasertib, several other targeted therapies are now available:
If you're struggling to access Capivasertib, one of these alternatives may be appropriate for your situation. Learn more in our guide to alternatives to Capivasertib.
Here are the most effective steps you can take right now:
Medfinder helps you identify specialty pharmacies that have Capivasertib available. Search for "Truqap" or "Capivasertib" and see real-time availability near you.
AstraZeneca's dedicated support program helps with everything from finding a pharmacy to navigating insurance. Call 844-275-2360 or visit MyAccess360.com.
Your cancer care team can expedite prior authorizations, appeal insurance denials, and coordinate with specialty pharmacies. Don't hesitate to ask for support — this is a normal part of accessing specialty medications.
Request refills at least 7–10 days in advance to allow for specialty pharmacy processing. Confirm that your prior authorization is still valid before each cycle.
For a full guide with step-by-step tips, read how to find Capivasertib in stock near you.
Capivasertib is not in a traditional drug shortage in 2026, but the access challenges patients face are real and frustrating. Between specialty pharmacy requirements, insurance prior authorizations, genetic testing, and high costs, getting your prescription filled can take time and persistence.
The most important thing is to not delay your treatment. Use the resources available to you — Medfinder, AstraZeneca Access 360, and your oncology team — to stay on track. And if Capivasertib isn't accessible right now, talk to your oncologist about whether an alternative therapy might be right for you in the meantime.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
